Literature DB >> 21925098

Role of regulatory T cell populations in controlling graft vs host disease.

Robert S Negrin1.   

Abstract

Immune function is critical in health and disease. The control and regulation of immune reactions is an area of intense investigation that has important implications for allogeneic hematopoietic cell transplantation. Immune reactions are regulated in a number of important ways. Compartmentalization of immune responses and the production of both pro-inflammatory and anti-inflammatory cytokines play a major role. More recently several populations of T cells that regulate immune responses termed regulatory T cells have been identified. This manuscript will focus on CD4+CD25+FoxP3+ natural regulatory T cells (T(reg)) and αβTCR+CD4+NK1.1+ natural killer T (NK-T) cells which both suppress graft vs host disease but appear to function by distinct mechanisms.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21925098      PMCID: PMC3176418          DOI: 10.1016/j.beha.2011.05.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  16 in total

Review 1.  Transplantation tolerance induced by "mega dose" CD34+ cell transplants.

Authors:  Y Reisner; M F Martelli
Journal:  Exp Hematol       Date:  2000-02       Impact factor: 3.084

2.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

3.  Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism.

Authors:  Dennis B Leveson-Gower; Janelle A Olson; Emanuela I Sega; Richard H Luong; Jeanette Baker; Robert Zeiser; Robert S Negrin
Journal:  Blood       Date:  2011-01-21       Impact factor: 22.113

4.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.

Authors:  Aurélie Trenado; Frédéric Charlotte; Sylvain Fisson; Micael Yagello; David Klatzmann; Benoit L Salomon; José L Cohen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

5.  Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.

Authors:  Stephen C Jones; George F Murphy; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

6.  The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation.

Authors:  Vu H Nguyen; Sumana Shashidhar; Daisy S Chang; Lena Ho; Neeraja Kambham; Michael Bachmann; Janice M Brown; Robert S Negrin
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

7.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

8.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.

Authors:  Matthias Edinger; Petra Hoffmann; Joerg Ermann; Kathryn Drago; C Garrison Fathman; Samuel Strober; Robert S Negrin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

9.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

View more
  4 in total

1.  Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Authors:  Shawn M Jensen; Christopher G Twitty; Levi D Maston; Paul A Antony; May Lim; Hong-Ming Hu; Ulf Petrausch; Nicholas P Restifo; Bernard A Fox
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

Review 2.  Prevention of graft-vs.-host disease.

Authors:  Andrew R Rezvani; Rainer F Storb
Journal:  Expert Opin Pharmacother       Date:  2012-07-07       Impact factor: 3.889

3.  Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Authors:  Alana A Kennedy-Nasser; Stephanie Ku; Paul Castillo-Caro; Yasmin Hazrat; Meng-Fen Wu; Hao Liu; Jos Melenhorst; A John Barrett; Sawa Ito; Aaron Foster; Barbara Savoldo; Eric Yvon; George Carrum; Carlos A Ramos; Robert A Krance; Kathryn Leung; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

Review 4.  Invariant natural killer T cells in hematopoietic stem cell transplantation: killer choice for natural suppression.

Authors:  P Guan; H Bassiri; N P Patel; K E Nichols; R Das
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.